Financial PerformanceThe 2024 EPS estimate is lowered to $2.91 from $3.00 due to a reduction in the 1Q24 estimate.
Integration ChallengesMerging two sizable organizations with different geographic footprints, sales forces, profitability profiles, cultures, and potentially strategic foci historically could lead to some choppiness as the integration proceeds.
Regulatory RiskManagement did not have an update on the FDA warning letter, which could pose a regulatory risk.